Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis.

ABSTRACT:

Purpose

We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH).

Materials and methods

A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib.

Results

The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO- group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The o

SUBMITTER: Yang Y 

PROVIDER: S-EPMC7812025 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature